Cytochrome P450 1A2 Genotype, Varies
Use
Identifying individuals who are poor, intermediate, normal (extensive) or rapid metabolizers of drugs metabolized by cytochrome P450 1A2 to assist drug therapy decision making.
Special Instructions
For cord blood specimens that have an accompanying maternal blood specimen, maternal cell contamination studies will be performed at an additional charge.
Limitations
Rare variants may be present that could lead to false‑negative or false‑positive results. Samples may contain donor DNA if obtained from patients who received non‑leukocyte reduced blood transfusions or allogeneic hematopoietic stem cell transplantation; genotype usually reverts to recipient within 6 weeks. CYP1A2 results in patients post–liver transplantation may not accurately reflect patient status. This method may not detect all variants; absence of detectable variant does not rule out altered metabolism; cis/trans status may not be known. Frequency of variants not fully characterized in all populations. CYP1A2 activity may be influenced by inhibitors, inducers.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 80687-7
- 72884-0
- 94254-0
- 69047-9
- 48767-8
- 85069-3
- 62364-5
- 18771-6
Result Turnaround Time
3-8 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
Not provided
Container
Lavender top (EDTA) or yellow top (ACD)
Collection Instructions
Invert several times to mix blood. Send whole blood specimen in original tube. Do not aliquot.
Patient Preparation
A previous hematopoietic stem cell transplant from an allogenic donor or a liver transplant will interfere with testing.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |
| Frozen | 4 days |